This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the multifactorial influences that contribute to Alzheimer's Disease progression.

More than 800 people from over 75 countries came together virtually on 3rd June 2025 for the eleventh edition of the RELX SDG Inspiration Day: "The Future of Philanthropy: Stepping up for the SDGs" The annual online event brings together together business, academia, NGOs and government to explore pressing issues and inspire action on the United Nations Sustainable Development Goals (SDGs). Explore highlights from the day including inspiring keynotes from Ban Ki-moon, 8th Secretary General of the United Nations, Sir Lenny Henry and Sarah, Duchess of York.

The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.
This study indicates neurofibrillary tangles(NFT) level detection in patients with extracranial carotid atherosclerotic disease (ECAD) could enable earlier identification of those at high risk for developing Alzheimer's and other dementias, sometimes decades before symptoms. As blood-based assays to quantify NFT's are more clinically available, this could guide more targeted prevention and early treatment strategies for patients.
This study investigated the prevalence and impact of auditory agnosia for environmental sounds in individuals with Alzheimer’s disease (AD), finding that over half exhibited signs of this central auditory dysfunction along with a high rate of unrecognized peripheral hearing loss. Although these factors appeared independent and showed limited direct effect on measured quality of life, possibly due to sheltered living environments and lack of patient awareness, they jointly contribute to daily functional decline, highlighting the importance of early hearing assessment and intervention in AD management.
The article discusses the need for and challenges of developing combination therapies for Alzheimer's disease, given the complex and multifactorial nature of the disease. As of 2024, there were 21 combination trials in the pipeline, primarily involving repurposed agents targeting processes like inflammation, senescence, and amyloid-tau interactions. Key challenges include distinguishing individual drug effects and managing the operational complexity of combination trials.f
Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 June 2025

This article provides a narrative review of the relationships between modifiable lifestyle factors and plasma biomarkers of Alzheimer's disease (AD). The key findings are that better nutrition, more physical activity, and good sleep quality are associated with more favorable plasma AD biomarker profiles, potentially reflecting less cerebral AD pathology.
The article discusses the critical role of the mitochondrial contact site and cristae organizing system (MICOS) complex in the pathogenesis of Alzheimer's disease (AD). It highlights how MICOS abnormalities, including subunit dysfunction and interactions with disease-associated proteins, to hallmark AD pathologies such as amyloid-β accumulation, neurofibrillary tangle formation, and neuronal apoptosis. The article suggests that targeting MICOS subunits with pharmacological interventions may provide novel therapeutic insights for AD treatment.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by exploring a novel area of research exploring the link between vascular disease and Alzheimer's Disease.

Elsevier,

Journal of Pharmacological Sciences, Volume 158, Issue 4, August 2025, Pages 310-321

The article investigates the role of CD38, an enzyme implicated in neuroinflammation and cellular senescence, in the context of vascular dementia (VaD). It demonstrates that inhibiting CD38 can mitigate cerebrovascular endothelial cell dysfunction, blood-brain barrier disruption, neuroinflammation, and white matter damage, ultimately alleviating cognitive impairment in a mouse model of VaD. The findings suggest that targeting CD38 may offer a promising therapeutic strategy for addressing the vascular and neurological deficits associated with VaD

Pages